NCT05757791View on ClinicalTrials.gov

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Major Depressive Disorder
Interventions
DRUG

Empagliflozin

The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.

Trial Locations (1)

10016

RECRUITING

NYU Langone Health, New York

All Listed Sponsors
collaborator

American Society of Clinical Psychopharmacology

UNKNOWN

lead

NYU Langone Health

OTHER